New Frontiers: Lantern Pharma Doses First Patient in AI-Guided Clinical Trial
Artificial intelligence company, Lantern Pharma Inc. (Nasdaq: LTRN), is advancing a pipeline of AI-driven therapies to patients. On Friday, the company announced it has dosed the first two patients in a Phase 1 clinical trial evaluating LP-284 in patients with hematologic cancers as well as other select solid tumors and sarcomas. Lantern’s share price rose by nearly 20% in morning trading following the news.
Lantern’s proprietary AI platform, RADR®, was instrumental in the development of LP-284 and aided in understanding its mechanism of action, identifying and prioritizing its cancer indications, and generating machine learning biomarker signatures to assist with patient selection in future clinical trials.
Panna Sharma, Lantern’s President and CEO, commented, “We believe LP-284 has unique and breakthrough potential for patients with relapsed or refractory lymphomas and certain solid tumors with certain genomic signatures, many of which have no or limited effective therapeutic options.
“LP-284 is a molecule which was advanced from initial concepts through IND-studies, manufacturing, multiple FDA-granted orphan indications, multiple patent filings, as well as presentations at major oncology conferences and into humans in a timeline and cost structure that is typically unheard of for a novel oncology-focused molecule. This milestone validates our unique approach of leveraging AI and machine learning to expedite cancer drug development,” said Sharma.
Lantern stated that it has been able to expedite LP-284’s journey from a concept to a first-in-human clinical trial in a highly efficient and cost-effective manner – less than 3 years and under $3 million – underscoring the power and potential of RADR® to accelerate oncology drug discovery and development.
LP-284 is being evaluated in the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymphomas (HGBL), and solid tumors.
The company’s open-label Phase 1a/1b multicenter Phase 1 trial is evaluating the safety and tolerability, and pharmacokinetics, of escalating doses of LP-284.
Lantern Pharma’s AI platform, RADR® is expected to exceed 100 billion data points during 2024, and has been crucial in uncovering and accelerating indications for LP-284 as well as other drug-candidates that are in development.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 – 2.5 million per program.
